Please assess the completion status of the following clinical trial:

Trial Title: EPR Tumor Oximetry With CE India Ink

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject must be capable of giving informed consent or has an acceptable surrogate capable of giving consent on behalf of the subject.~2. Subject has an eligible tumor that is within 5 mm of the surface (either skin or mucosa) or has had a tumor removed with a tumor bed that is within 5 mm of the surface.~   1. Eligible tumors types:~      * Intraoral tumors: squamous cell carcinoma (SCC), melanoma;~     * Primary cutaneous tumors (including, but not limited to): SCC, basal cell carcinoma (BCC,) melanoma;~     * Breast malignancies post surgery;~     * Other tumors: any tumor within 5 mm of the surface and with planned radiation therapy.~Exclusion Criteria:~1. Previous adverse reaction to a charcoal product e.g., a local hypersensitive response from a black tattoo or from ingestion of activated charcoal~2. Previous adverse reaction to the suspending agent~3. Subject has a pacemaker that is not known to be MRI compatible~4. Subject has a non-removable implant or device with metal that is not known to be MRI compatible~5. Subject is pregnant or has a likelihood for becoming pregnant during the basic study timeframe.~Note: There is no known harm to the woman or her fetus from participating; this is precautionary only.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: Intraoral Squamous Cell Carcinomas (Type: None): Intraoral squamous cell carcinomas that are resected and receive adjuvant radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), or in both instances. Patients whose tumor is within 5 mm of the surface will have injections of India ink into the tumor itself and measurements made in the tumor prior to surgery. Patients whose tumor is deeper than 5 mm of the surface could participate only in the measurements of the postsurgical radiation field. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the postsurgical radiation field as appropriate.
- 2: Cutaneous Malignant Tumors (Type: None): Patients with primary cutaneous malignant tumors (including but not limited to squamous cell carcinoma, basal cell carcinoma, or melanoma) whose tumor is within 5 mm of the surface and whose treatment plan includes surgical resection and/or postsurgical radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), in both the tumor and the postsurgical radiation field, or in the tumor prior to radiation therapy. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the tumor or postsurgical radiation field as appropriate.
- 3: Breast Cancers (Type: None): Breast cancer patients whose treatment plan includes surgical resection followed by radiation therapy. All patients who receive a surgical resection will receive a Carlo Erba Ink injection in the radiation field after sufficient healing has occurred to the area to be injected, as determined in consultation with the treating physicians, and using topical anesthetic or local anesthetic, if the patient so desires. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
- 4: Other tumors (Type: None): Other tumors within 5 mm of the surface, whose planned treatment includes radiotherapy of the tumor and does not include a planned resection of the tumor. As these other qualifying malignancies are expected to occur only rarely, they will be grouped into a single cohort despite potential varied histology. These patients will receive a Carlo Erba Ink injection in their tumor prior to radiation therapy. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).